Reaction
Aspiration Pleural Cavity reporting signals
As of the last recalculation, Aspiration Pleural Cavity appears in 763 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is EPOPROSTENOL (PRR 69.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epoprostenol | 32 | 69.6 | 69.7 |
| Dasatinib | 60 | 47.7 | 47.8 |
| Macitentan | 85 | 37.6 | 37.6 |
| Imatinib Mesylate | 23 | 23.2 | 23.2 |
| Sildenafil Powder, | 27 | 21.4 | 21.4 |
| Niraparib | 16 | 20.1 | 20.1 |
| Metolazone | 8 | 19.6 | 19.6 |
| Bosentan | 32 | 18.0 | 18.0 |
| Selexipag | 16 | 17.2 | 17.2 |
| Sildenafil | 35 | 17.2 | 17.2 |
| Riociguat | 19 | 16.3 | 16.3 |
| Nivolumab | 51 | 15.4 | 15.4 |
| Rucaparib | 4 | 12.4 | 12.4 |
| Bosutinib | 4 | 12.2 | 12.2 |
| Ambrisentan | 33 | 7.5 | 7.5 |
| Tafamidis | 3 | 7.0 | 7.0 |